The Latest Cardiac and Vascular News
Phase 1b Clinical Trial, heart-1, Now Underway and Enrolling Patients with Heterozygous Familial Hypercholesterolemia in New Zealand Company Executing VERVE-101 Global Regulatory Strategy with Potential Clearances for a UK Clinical Trial Application and US Investigational New Drug Application in Second Half of 2022 CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) […]
NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that rexlemestrocel-L, its allogeneic “off-the-shelf” product candidate for the treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF), will be highlighted in a panel discussion […]
RA’ANANA, Israel, July 11, 2022 /PRNewswire/ — Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira Technologies”) introduces today the “Liby™” System, an advanced form of life support better known by the medical industry as extracorporeal membrane oxygenation (ECMO), used to treat patients with life-threatening heart and lung failure. The Liby™ System is intended to […]
Abelacimab is a dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa with high affinity and selectivity Earlier this year abelacimab became the first-ever Factor XI inhibitor to begin enrolling patients in a Phase 3 trial (The ASTER Study) The AZALEA-TIMI 71 trial in patients with atrial fibrillation […]
New health economics research on polygenic risk score (PRS) for cardiovascular disease published in the Journal of the American Heart Association highlights the cost savings of PRS testing for US healthcare systems NEW YORK, July 7, 2022 /PRNewswire/ — Allelica, a leading genomic software company specializing in secure and scalable solutions to implement […]
Tenaya’s Precision Medicine Platform Used to Identify HDAC6 Target Using Phenotypic Screening and Machine Learning Algorithms Tenaya’s HDAC6 Inhibitor TN-301 Advancing to the Clinic for HFpEF, with IND Filing on Track for 2H 2022 SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a […]
New study from UH Harrington Heart & Vascular Institute shows link between historical redlining and increase in contemporary cardiometabolic health risk factors CLEVELAND — A new study from University Hospitals (UH) Harrington Heart & Vascular Institute further proves that people living in areas that were subjected to housing discrimination decades […]
The 2022 CytoSorb World Users’ Meeting focuses on groundbreaking new applications of the adsorption technology to celebrate the 10th anniversary of commercialization PRINCETON, N.J. and BERLIN, July 1, 2022 /PRNewswire/ — Under the theme “We Are Changing Medicine: CytoSorb Therapy – From the Past to the Future,” CytoSorbents Corporation (NASDAQ: CTSO) is bringing together nearly 300 of the […]
REVERSE-HF will evaluate ultrafiltration therapy in comparison to IV diuretics to treat heart failure patients with fluid overload MINNEAPOLIS, June 29, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) today announced the first patient has been enrolled in the company’s pivotal REVERSE-HF (Ultrafiltration Versus IV Diuretics in Worsening Heart Failure) clinical study. REVERSE-HF will evaluate […]
Positive Data for Istaroxime in Early Cardiogenic Shock Brings Notable Interest from Potential Partners WARRINGTON, Pa., June 29, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for acute cardiovascular disorders, today provided an update to its strategy and pursuit related to […]
